很抱歉,您的瀏覽器過於老舊無法閱讀網頁內容的需要,請更新瀏覽器或安裝 Google Chrome.

Investor Relations

Announcement

Senhwa announces FDA clearance of IND application for CX-5461 combined with BeOne Medicines’ Tislelizumab global trial in multiple advanced/metastatic solid tumors

Senhwa announces FDA clearance of IND application for CX-5461 combined with BeOne Medicines’ Tislelizumab global trial in multiple advanced/metastatic solid tumors

Jun
02
2026

Event

Senhwa Biosciences, Inc. will attend the institutional investor conference invited by Cathay Securities Corporation.

Senhwa Biosciences, Inc. will attend the institutional investor conference invited by Cathay Securities Corporation.

1.Date of institutional investor conference:2025/12/23
2.Time of institutional investor conference: 14:00 (Taiwan time)
3.Location of institutional investor conference: 18F, No. 333, Sec. 2, Dunhua S. Rd., Da'an Dist., Taipei City, Taiwan(Cathay Securities Headquarters)
4.Outline of institutional investor conference: The Company will attend Cathay Securities' investor conference to update the Company's business operations.
5.Any other matters that need to be specified: None. Related information will be disclosed on MOPS

Conference video link: https://youtu.be/dppsCUH5Vyw

Dec
17
2025